Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 109 of 5804
-
Sound waves could tame Parkinson's tremors and twitches
Disease control OngoingEvaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic Parkinson's disease.
Phase: NA • Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for Hard-to-Treat colorectal cancer: immunotherapy combo under trial
Disease control OngoingThis phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in th…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Immunotherapy combo aims to extend lives in aggressive breast cancer
Disease control CompletedThis study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThe purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after …
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could this antibody slow Alzheimer's? new trial results are in
Disease control CompletedThe purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immunotherapy shows promise against advanced liver cancer
Disease control CompletedThis Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not be surgically removed. Before enrolling Japanese pa…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
Disease control CompletedThe purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancrea…
Phase: PHASE1, PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New Alzheimer's vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedAlzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide. The amyloid cascade hypothesis of AD proposes that amyloid-β (Aβ) peptide accumulation in the brain, caused by an imbalance between Aβ p…
Phase: PHASE2 • Sponsor: Araclon Biotech S.L. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Gene therapy takes on deadly brain tumors in new trial
Disease control Recruiting nowStudy to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Phase: PHASE1, PHASE2 • Sponsor: David Baskin MD • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising drug cocktail aims to hold multiple myeloma at bay longer
Disease control OngoingPrimary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and dexamethasone, in participants with newly diagnosed mu…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThe purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental drug hopes to boost chemo against tough pancreatic cancer
Disease control CompletedAntroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. …
Phase: PHASE1, PHASE2 • Sponsor: Golden Biotechnology Corporation • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
One-Shot wonder? huge study tests single HPV vaccine dose
Prevention OngoingThis phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer. Vaccines that protect against infection with these ty…
Phase: PHASE4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 26, 2026 14:06 UTC
-
New combo therapy shows promise against Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotherapy…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immune cell therapy takes on tough blood cancers
Disease control OngoingThis is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or…
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
A quick pill and an EEG may spot schizophrenia in hours, not years
Diagnosis OngoingSchizophrenia is a severe psychotic illness of unknown cause that affects 1% of the population worldwide. Currently, there is no diagnostic test for schizophrenia. Instead, the diagnosis is typically established through a psychiatric interview of the patient, who is evaluated aga…
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Can less be more? new trial aims to treat brain tumors with fewer side effects
Disease control OngoingThis phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy a…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New lymphoma combo shows promise in major trial
Disease control CompletedThis Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a shot keep smoldering myeloma from igniting?
Disease control CompletedThe primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo slows myeloma progression in Late-Stage trial
Disease control CompletedThe purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC